SAN DIEGO, Feb. 18, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Company will host its fiscal second quarter 2016 financial results conference call on Tuesday, March 8 at 1:15 PM PT/4:15 PM ET. To listen to the conference call, please dial (877) 731-1960 and use conference ID number: 50125992. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website: ir.oncosec.com/events.
About OncoSec Medical Incorporated OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.
Contact Mary Marolla OncoSec Medical Incorporated 855-662-6732 email@example.com
SOURCE OncoSec Medical Incorporated